



MAR 02 2000

TECH CENTER 1600/2900

Patent Docket No. P1543R1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Dominick V. Sinicropi et al. Serial No.: 09/449,204 Filed: November 24, 1999 For: PCR ASSAY	 Examiner: not assigned Art Unit: 1643 CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 20231 on February 25, 2000  Glory L. Tabuena
--	---

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR
PATENT APPLICATION CONTAINING SEQUENCE DISCLOSURES

Box Sequence
Assistant Commissioner for Patents
Washington, DC 20231

Sir:


In response to the Notice to Comply mailed December 27, 1999, transmitted herewith are the following documents:

1. Form PTO-1661;
2. Sequence Listing and computer-readable diskette; and
3. return self-addressed postcard.

The Commissioner is authorized to charge any additional fees due in connection with the filing of these documents to our Deposit Account No. 07-0630 (our Ref. P1543R1). A duplicate copy of this transmittal is enclosed.

Respectfully submitted,
GENENTECH, INC.

Date: February 25, 2000

By: 
Timothy R. Schwartz, Ph.D.
Reg. No. 32,171



1 DNA Way
South San Francisco, CA 94080-4990
Phone: (650) 225-7467
Fax: (650) 952-9881

#72018

RECEIVED
MAR - 6 2000
TC 1600 MAIL ROOM

GP1643 WD
Box Seg.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Dominic V. Sinicropi et al. Serial No.: 09/449,204 Filed: November 24, 1999 For: PCR ASSAY	 Group Art Unit: 1643 Examiner: not assigned
	<p>CERTIFICATE OF MAILING</p> <p>I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 20231 on</p> <p>February 25, 2000</p> <p> Glory L. Tabuena</p>

CERTIFICATE RE: SEQUENCE LISTING
RESPONSE UNDER 37 CFR § 1.821(f) and (g)

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

I hereby state that the Sequence Listing submitted herewith is submitted in paper copy and a computer-readable diskette, and that the information recorded in computer readable form is identical to the written sequence listing. I further state that this submission includes no new matter.

Respectfully submitted,


GENENTECH, INC.

Date: February 25, 2000

By: 

Timothy R. Schwartz, Ph.D.
Reg. No. 32,171

1 DNA Way
South San Francisco, CA 94080-4990
Phone: (650) 225-7467
Fax: (650) 952-9881



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARK
Washington, D.C. 20231

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO./TITLE
--------------------	---------------------	-----------------------	---------------------------

09/449,200 11/24/99 SINICROPI D P1543R1
0262/1227
TIMOTHY R SCHWARTZ PH D NOT ASSIGNED
GENENTECH INC
1 DNA WAY
SOUTH SAN FRANCISCO CA 94080-4990
1643
DATE MAILED: 12/27/99

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

An Application Number and Filing Date have been assigned to this application. The items indicated below, however, are missing. Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file a sequence listing in compliance with 37 CFR 1.821- 1.825 to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):

- ☐ 1. This application fails to comply with the requirements of 37 CFR 1.821 - 1.825.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
- ☒ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
- ☐ 7. OTHER:

APPLICANT MUST PROVIDE:

- ☐ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing."
- ☐ An initial or substitute paper copy of the "Sequence Listing," as well as an amendment directing its entry into the specification.
- ☐ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).

FOR QUESTIONS REGARDING COMPLIANCE WITH THESE REQUIREMENTS, PLEASE CONTACT:

- ☐ For Rules Interpretation, call (703) 308-1123.
- ☐ For CRF submission help, call (703) 308-4212.
- ☐ For Patent software help, call (703) 308-6856.

AVAILABLE COPY

Washington
Customer Service Center
Initial Patent Examination Division (703) 308-1202

27 Feb 2000

PART 2-COPY TO BE RETURNED WITH RESPONSE